Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Toray Of Japan Accelerates Anti-Itching Agent Clinical Trails In Europe And U.S.

This article was originally published in PharmAsia News

Executive Summary

Currently under approval review in Japan, Toray has sped up the clinic trials overseas for anti-itching agent TRK-820, jointly developed by Toray, Japan Tobacco, Torii Pharma and Maruo Co. In Europe, TRK-820 injection has entered a Phase III trial, and a Phase III trial for TRK-820 oral dose has begun in the U.S. TRK-820 is an opioid k receptor agonist for treating uremic pruritis in hemodialysis patients. Toray hopes to get TRK-820 oral dose approved in Japan within this year. The company also announced that urinary incontinence drug TRK-130 has entered Phase II trials in Japan. (Click here for more - Japanese language

Latest Headlines
See All
UsernamePublicRestriction

Register

SC068328

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel